Opca Bolnica Zadar
- Address
- lock Available on a paid plan
Opca Bolnica Zadar - Multispecialty Clinical Research Center
Opca Bolnica Zadar is a comprehensive clinical research center in Croatia specializing in diverse therapeutic areas. The facility demonstrates extensive capabilities in conducting complex Phase 2 and Phase 3 clinical trials across multiple medical specialties, with particular emphasis on chronic disease management and novel therapeutic interventions.
- Respiratory diseases including COPD and severe eosinophilic asthma with expertise in maintenance triple therapy and exacerbation reduction studies
- Autoimmune and inflammatory conditions encompassing Crohn's disease, ulcerative colitis, systemic lupus erythematosus, systemic sclerosis, and IgA nephropathy
- Cardiovascular and metabolic disorders including atrial fibrillation anticoagulation trials and severe hypertriglyceridemia management
- Rheumatologic conditions such as psoriatic arthritis and specialized immunology research in celiac disease
The center maintains advanced research infrastructure for studying biologic therapies, oral targeted therapies, and subcutaneous formulations. Their portfolio includes innovative studies in hematologic malignancies like follicular lymphoma, ophthalmologic conditions including neovascular age-related macular degeneration, and neurological disorders such as multiple sclerosis. The facility's participation in international multi-center trials demonstrates its commitment to advancing medical science through rigorous evaluation of disease-modifying treatments and novel pharmacological interventions across various medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Opca Bolnica Zadar
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 2 | Unknown | 2025-06-26 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.